Research map: Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment

Back to the article

Papers in this map

  1. Triple-negative breast cancer molecular subtyping and treatment progress · Li Yin · 2020 · 2607 citations · Cited by this paper
  2. Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models · 2026 · Related
  3. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing · Charissa R. Kim · 2018 · 1208 citations · Cited by this paper
  4. Self-sufficient killing of malignant tumors by an engineered cancer-selective gene circuit · 2026 · Related
  5. Advances in systemic therapies for triple negative breast cancer · Roberto Antonio Leon-Ferre · 2023 · 510 citations · Cited by this paper
  6. Persistent cytolytic CD8+ T cells recognize SARS-CoV-2 and herpesvirus epitopes in long COVID · 2026 · Related
  7. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development · Ayechew Adera Getu · 2023 · 244 citations · Cited by this paper
  8. Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination · 2026 · Related
  9. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy · Binghao Zhao · 2022 · 205 citations · Cited by this paper
  10. Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cells · 2026 · Related
  11. Mechanisms of Resistance to Antibody–Drug Conjugates · Rachel O. Abelman · 2023 · 153 citations · Cited by this paper
  12. Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice · 2026 · Related
  13. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer · Mythili Shastry · 2022 · 147 citations · Cited by this paper
  14. Köhlmeier-Degos disease is an interferonopathy characterized by type I and II interferon-driven inflammatory vasculopathy · 2026 · Related
  15. Directed Therapy of Subtypes of Triple-Negative Breast Cancer · Lisa A. Carey · 2011 · 135 citations · Cited by this paper
  16. Metabolomic and lifestyle profiles refine BMI-metabolic phenotypes in older adults · 2026 · Related
  17. Breast Cancer Detection by B7-H3–Targeted Ultrasound Molecular Imaging · Sunitha V. Bachawal · 2015 · 131 citations · Cited by this paper
  18. Alterations of the host-lung microbiome metasystem in systemic inflammatory response syndrome is associated with secondary pneumonia · 2026 · Related
  19. B7-H3 Immune Checkpoint Protein in Human Cancer · Karine Flem Karlsen · 2019 · 79 citations · Cited by this paper
  20. An autonomous multimodal AI agent for evidence-grounded ophthalmic diagnosis · 2026 · Related
  21. Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and Validation · Yingnan Si · 2019 · 78 citations · Cited by this paper
  22. A Dual-Payload Antibody–Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer · Zhuoxin “Zora” Zhou · 2024 · 48 citations · Cited by this paper
  23. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy · Yingnan Si · 2020 · 46 citations · Cited by this paper
  24. Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy · Yingnan Si · 2020 · 38 citations · Cited by this paper
  25. The treatment landscape of triple-negative breast cancer · Yi Hu · 2024 · 38 citations · Cited by this paper
  26. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research · José Rodrigo Espinosa Fernández · 2020 · 37 citations · Cited by this paper
  27. Precisely Control Mitochondria with Light to Manipulate Cell Fate Decision · Patrick J. Ernst · 2019 · 35 citations · Cited by this paper
  28. Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer · Yingnan Si · 2021 · 29 citations · Cited by this paper
  29. Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment · Idil Buyukgolcigezli · 2025 · 28 citations · Cited by this paper
  30. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment · Yingnan Si · 2020 · 27 citations · Cited by this paper
  31. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma · Kai Chen · 2022 · 27 citations · Cited by this paper
  32. Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers · Yingnan Si · 2022 · 24 citations · Cited by this paper
  33. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back · Valentina Rossi · 2024 · 20 citations · Cited by this paper
  34. mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer · Kai Chen · 2024 · 18 citations · Cited by this paper
  35. Detection and Characterization of Sentinel Lymph Node by Ultrasound Molecular Imaging with B7-H3-Targeted Microbubbles in Orthotopic Breast Cancer Model in Mice · Zhongqian Hu · 2021 · 17 citations · Cited by this paper
  36. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs · Attrayo Mukherjee · 2024 · 17 citations · Cited by this paper
  37. Antibody–Drug Conjugate to Treat Meningiomas · Kai Chen · 2021 · 14 citations · Cited by this paper
  38. A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC) · Jiashuai Zhang · 2023 · 12 citations · Cited by this paper
  39. The role of ado-trastuzumab emtansine in current clinical practice · Alla Turshudzhyan · 2020 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)